Scarica l'app Stockscreener
15.49
5.02%
0.74
Dopo l'orario di chiusura:
15.60
0.11
+0.71%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RLAY Giù?
Forum
Previsione
Relay Therapeutics Inc Borsa (RLAY) Ultime notizie
Relay Therapeutics (RLAY) climbs 16% ahead of cancer treatment update - MSN
Jones Trading initiates coverage of Relay Therapeutics (RLAY) with hold recommendation - MSN
Relay Therapeutics (RLAY) surges 16.4%: Is this an indication of further gains? - MSN
RLAY Initiated Coverage by Jones Trading -- Rating Set to Hold - GuruFocus
JonesTrading Initiates Coverage on Relay Therapeutics (NASDAQ:RLAY) - MarketBeat
Perceptive Fund (RLAY) reports 9.99% ownership — 438,471 shares - Stock Titan
Relay Therapeutics CFO Sells $27,000 in Stock - National Today
Relay Therapeutics CFO Sells $27,000 in Shares - National Today
Relay Therapeutics stock hits 52-week high at 14.98 USD By Investing.com - Investing.com Canada
Relay Therapeutics Hits New 52-Week High After Analyst Upgrade - National Today
Earnings Recap: Will Relay Therapeutics Inc benefit from green energy policies2026 Action & Reliable Entry Point Alerts - baoquankhu1.vn
Catinazzo, Relay Therapeutics CFO, sells $257k in RLAY stock By Investing.com - Investing.com Australia
Catinazzo, Relay Therapeutics CFO, sells $257k in RLAY stock - Investing.com
Relay Therapeutics (NASDAQ: RLAY) CFO logs 19,517-share sale under 10b5-1 plan - Stock Titan
Rally Mode: Will Relay Therapeutics Inc benefit from government policyRate Cut & Step-by-Step Swing Trade Plans - baoquankhu1.vn
Relay Therapeutics stock hits 52-week high at 14.98 USD - Investing.com
Barclays Raises Price Target for Relay Therapeutics (RLAY) to $2 - GuruFocus
Barclays Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Raises Target Price to $21 - Moomoo
JPMorgan Chase & Co. Reduces Position in Relay Therapeutics, Inc. $RLAY - MarketBeat
Relay Therapeutics, Inc. (RLAY) stock price, news, quote and history - Yahoo Finance Singapore
Relay Therapeutics, Inc. (RLAY) Discusses Mutant Selective PI3K-alpha Inhibitor for PIK3CA-Driven Vascular AnomaliesSlideshow (NASDAQ:RLAY) 2026-04-06 - Seeking Alpha
Relay Therapeutics (RLAY) Jumps 16.4%: Does This Signal More Upside Ahead? - Bitget
Relay Therapeutics (RLAY) Surges 16.4%: Is This an Indication of Further Gains? - Yahoo Finance
SG Americas Securities LLC Acquires 189,004 Shares of Relay Therapeutics, Inc. $RLAY - MarketBeat
Is Relay Therapeutics (RLAY) Building a Durable Precision-Medicine Platform with Its Zovegalisib Strategy? - Sahm
Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Aug Highlights: Can Relay Therapeutics Inc scale operations efficiently2026 Short Interest & Weekly High Return Stock Opportunities - baoquankhu1.vn
Relay Therapeutics (RLAY) Is Up 30.6% After Expanding Zovegalisib Into Vascular Anomalies Data Reveal - Yahoo Finance
Which Is a Better Investment, ACADIA Pharmaceuticals Inc. or Relay Therapeutics, Inc. Stock? - AAII
Relay Therapeutics (NASDAQ:RLAY) Reaches New 52-Week HighTime to Buy? - MarketBeat
Relay Therapeutics to Present Initial Clinical Data on Zovegalisib in Vascular Anomalies at the International Society for the Study of Vascular Anomalies World Congress 2026 - Sahm
Relay Therapeutics to Present Initial Clinical Data on Zovegalisib at Vascular Anomalies Conference - National Today
Relay Therapeutics (RLAY) Climbs 16% Ahead of Cancer Treatment Update - insidermonkey.com
5 Stocks With Easy 8-20% Gains - Insider Monkey
Relay Therapeutics stock hits 52-week high at $11.52 By Investing.com - Investing.com Australia
Relay Therapeutics to Present Initial Clinical Data on - GlobeNewswire
2.69%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):